HGH Fragment 176-191 is a 16-amino-acid C-terminal fragment of human growth hormone (hGH). It has attracted research interest because certain C-terminal GH fragments have demonstrated effects on lipid metabolism and fat oxidation in experimental models.

Product Information

The native hGH 176-191 fragment should be distinguished from AOD-9604, a related but chemically distinct GH-derived peptide that has been studied in humans. Most of the commonly cited fat-loss literature belongs to AOD-9604 or other GH fragments rather than the native 176-191 sequence itself.

How It Works

Preclinical research has investigated C-terminal GH fragments for effects on lipid metabolism, including lipolysis and fat oxidation. The mechanism is distinct from full-length growth hormone and does not simply reproduce the complete GH/IGF-1 signaling profile.

POTENTIAL BENEFITS

1. Lipolysis Research

C-terminal GH-fragment research has examined whether specific portions of the hormone can influence the breakdown of stored fat. Animal studies have provided the primary evidence supporting this research direction.

2. Fat-Oxidation Research

Experimental studies have investigated increased fatty-acid utilization following exposure to GH-derived fragments. These findings have helped drive interest in the fragment as a model for selective metabolic signaling.

3. Metabolic Research

The fragment provides a way to investigate biological activity within a specific region of the larger GH molecule. This is useful for studying whether metabolic effects can occur independently of full-length GH activity.

4. GH-Fragment Research

HGH Fragment 176-191 is particularly relevant to structure-function research examining how different regions of growth hormone contribute to biological effects. Evidence for the native fragment itself remains predominantly preclinical.

Dosage

There is no established human dosage for native HGH Fragment 176-191. Published human clinical research commonly associated with this peptide concerns the related compound AOD-9604, which should not be treated as identical to the native 176-191 sequence. Animal doses therefore should not be presented as validated human dosing.

Side Effects

Human safety data for native HGH Fragment 176-191 are insufficient. Because the exact fragment has not undergone a meaningful clinical development program, its human pharmacokinetics, tolerability, and long-term safety remain incompletely characterized.

References

1. Ng FM, et al. *Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.*
2. Ng FM, et al. Research on C-terminal growth hormone fragments and metabolic activity.
3. AOD-9604 and GH-fragment human research review.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.